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Letters to the EditorVitamin D deﬁciency and HCV chronic infection: What comes ﬁrst?To the Editor:
Dear Sir, we read with great interest the paper published by
Lange et al. [1] reporting that serum vitamin D deﬁciency
and the CYP27B1-1260 promoter polymorphism are more pre-
valent in patients with chronic hepatitis C compared to con-
trols, and that they are associated with a lower response rate
to interferon-alfa based therapy. Comparing patients with
chronic hepatitis C to a large control group, the authors found
a strong association between the presence of chronic hepatitis
C and severe vitamin D (25-OH D3) deﬁciency (serum lev-
els <10 ng/ml in 25% of the patients vs. 12% of controls,
p <0.00001). Furthermore, adding new observations to the
recently published data [2], the authors showed that serum
vitamin D deﬁciency is associated with a lower probability to
achieve sustained viral response (SVR) after antiviral therapy
in easy to treat hepatitis C virus (HCV) genotypes.
The association between vitamin D deﬁciency and HCV
chronic infection has been previously reported by several
authors [3] and different studies demonstrated that it seems
to be preferentially related to the HCV etiology rather than
to the severity of liver disease [4]. These observations raise
the question about what comes ﬁrst, vitamin deﬁciency or
HCV infection? In other words, may vitamin D deﬁciency con-
fer an enhanced susceptibility to HCV chronic infection, or can
HCV chronic infection, through a still unknown mechanism,
cause vitamin D deﬁciency?
To try to answer this question Dr. Lange et al. [1] examined
whether the eradication of HCV infection determined a signiﬁ-
cant increase in the serum levels of vitamin D. They determined
25-OH D3 serum concentrations before and 24 weeks after the
end of antiviral therapy, in 50 patients with HCV genotype 1
chronic hepatitis who achieved SVR. Although in these patients
the median value of 25-OH D3 serum concentrations increased
slightly 24 weeks after the end of antiviral treatment (16.2 vs.
18.2 ng/ml), the authors outlined that a trend for having a lower
prevalence of severe vitamin D deﬁciency (25-OH D3 <10 ng/ml)
after HCV eradication has been detected (33% vs. 26%, p = 0.092).
Hence the authors speculate that HCV infection itself may affect
vitamin D metabolism, providing preliminary evidence that a
potential direct viral effect on vitamin D synthesis could be
hypothesized.
Although this assumption may be acceptable, we are not
completely convinced that this can be supported by the data
presented, not only for the lack of statistically signiﬁcance they
have. In the analysis of vitamin D serum concentrations, the
authors did not consider the season in which the serum sample
was taken, that represent a very important variable able to
inﬂuence vitamin D serum concentration [5]. Analyzing a
cohort of 211 north-Italian patients with chronic HCV related
hepatitis treated with pegylated interferon and ribavirin, we
identiﬁed as independent predictors of low (620 ng/ml), vita-
min D serum levels the age >50 years (O.R. 2.37, 95% C.I.
1.34–4.21, p = 0.002) and having drawn the blood sample forJournal of Hepatologyvitamin D measurement during the winter or spring months
(O.R. 2.06, 95% C.I. 1.15–3.67, p = 0.016). When the analysis
was performed in the subgroup of the 144 patients who under-
went a pre antiviral treatment liver biopsy, a higher histology
grade (O.R. 3.42, 95% C.I. 1.37–8.54, p = 0.004) and having
drawn the blood sample for vitamin D measurement during
the winter or spring months (O.R. 2.79, 95% C.I. 1.35–5.74,
p = 0.005) were the only independent predictors of low vitamin
D serum levels [6].
As the authors evaluated vitamin D serum levels 24 weeks
after the end of antiviral therapy, it is inevitable that the sea-
son in which the second assessment of the vitamin D serum
levels was made can not be the same of the ﬁrst determina-
tion. Thus the change in vitamin D serum levels in patients
who achieved SVR, observed by Lange et al. [1], may be prefer-
entially due to the season inﬂuence rather than to the eradica-
tion of HCV infection. Since the time in which antiviral therapy
has been started is generally an easily recoverable data, the
authors should analyze their data taking into account this
important variable in order to conﬁrm the association they
found towards a lower prevalence of vitamin D deﬁciency in
patients who achieved SVR.
In conclusion, it seems evident that a close interplay between
low vitamin D serum levels and HCV chronic infection exist, but,
until now, we still do not know what come ﬁrst.
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Reply to ‘‘Vitamin D deﬁciency and HCV chronic infection:
What comes ﬁrst?’’
To the Editor:
We thank Dr. Bitetto et al. for their interest in our study recently
published in the Journal of Hepatology [1]. In this study, we
reported a high prevalence of severe vitamin D deﬁciency in
patients with chronic hepatitis C, even in the absence of signiﬁ-
cant liver ﬁbrosis. We found that vitamin D deﬁciency was asso-
ciated with failure to achieve a sustained virologic response (SVR)
to therapy of chronic hepatitis C with pegylated interferon-alfa
and ribavirin. Bitetto et al. have now accentuated the important
question, whether vitamin D deﬁciency is caused by hepatitis C
virus (HCV) infection, or whether vitamin D deﬁciency may
confer an enhanced susceptibility to chronic HCV infection. We
believe that this question cannot be ﬁnally answered at the
moment. In our study, we reported a slight increase of
25-hydroxyvitamin D serum levels from baseline to week 24 after
completion of antiviral therapy in those patients who achieved a
SVR. As highlighted by Bitetto et al. and others [2,3], we have
made an attempt to stratify the patients included in this
sub-analysis according to the season in which serum samples
for vitamin D measurement were taken. In detail, 50% of patients
started therapy in winter/spring and SVR was ascertained in
summer/autumn, which was vice versa in the remaining 50% of
patients. Meanwhile, we have also re-analyzed our complete
cohort according to the season when baseline serum samples
for vitamin D detection were taken. Although we observed
slightly lower baseline 25-hydroxyvitamin D serum levels in
patients who started therapy in winter/spring compared to sum-
mer/autumn (mean 16.6 and 18.7 ng/ml, p = 0.054), severe vita-
min D deﬁciency (<10 ng/ml) was associated with chronic HCV
infection during all seasons (26% vs. 19% in winter/spring vs. sum-
mer/autumn, respectively, compared to 20% vs. 6% in winter/
spring vs. summer/autumn samples in our non-HCV infected con-
trol group). In addition, season had no signiﬁcant inﬂuence on
SVR rates. Nevertheless, we fully agree with Bitetto et al. that
our observations do not prove that HCV infection itself can cause
vitamin D deﬁciency. In addition to a residual season inﬂuence,
factors such as changes in life-style or eating habits may contrib-
ute to the increase of vitamin D serum levels after successful HCV
eradication. To resolve the ‘‘what comes ﬁrst’’ question results of
basic research on a potential interplay between HCV infection
and vitamin D metabolism, as well as additional clinical data
from large and well deﬁned patient cohorts are required.
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Tips for portal vein thrombosis (pvt) in cirrhosis: Not only
unblocking a pipe
To the Editor:
Han et al. recently published a case series of patients with cirrhosis
whohaddevelopedportalandsplanchnicvein thrombosis atvarious
intervals from treatment with transjugular intrahepatic portosys-
temic shunt (TIPS), for complications of the resulting portal hyper-
tension [1]. We are pleased that they conﬁrmed our published
ﬁndings that TIPS is feasible and effective in patients with PVT,
including thosewithcavernous transformationof theportal vein [2].
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